<SEC-DOCUMENT>0001188112-14-000804.txt : 20140507
<SEC-HEADER>0001188112-14-000804.hdr.sgml : 20140507
<ACCEPTANCE-DATETIME>20140326161545
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001188112-14-000804
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20140326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	INDUSTRIAL ORGANIC CHEMICALS [2860]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify"><img src="image_001.jpg" alt="adnas" style="height: 69px; width: 333px"></td>
    <td style="width: 50%; font: 10pt Times New Roman, Times, Serif; padding: 5px 5.4pt 12pt 203px; text-align: justify"><img src="image_002.jpg" alt="adnas" style="height: 70px; width: 120px"></td></tr>
</table>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">March 26, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B><U>VIA EDGAR</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left">Mr. John Cash<BR>
Accounting Branch Chief<BR>
United States Securities and Exchange Commission<BR>
Division of Corporation Finance<BR>
100 F Street, N.E.<BR>
Washington, D.C. 20549</P>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 8%; font: bold 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 24pt; text-indent: 0in"><font style="font-size: 10pt">Re:</font></td>
    <td style="width: 92%; font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><font style="font-size: 10pt">Applied DNA Sciences, Inc.</font><br>
<font style="font-size: 10pt">Form 10-K for the Year Ended September 30, 2013</font><br>
<font style="font-size: 10pt">Filed December 20, 2013</font><br>
<font style="font-size: 10pt">File No. 2-90539</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Dear Mr. Cash:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We have set forth below the response
of Applied DNA Sciences, Inc. (the &ldquo;Company&rdquo;) to the comments received from the staff of the Division of Corporation
Finance (the &ldquo;Staff&rdquo;) of the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) by letter dated March
12, 2014 (the &ldquo;Comment Letter&rdquo;), with respect to the above-referenced Annual Report on Form 10-K (the &ldquo;10-K&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">For ease of reference,
the Staff&rsquo;s comments are set forth in italic type immediately before the corresponding response. Where indicated below, we
have included proposed disclosure to be included in our future filings.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Item 1. Business, page 1</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Present Markets, page 6</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">1. We note your response to comment
one in our letter dated February 20, 2014. In future filings, for each listed Present Market, please clarify if you are currently
selling your products in that market or if you plan to do so in the near future. For example, we note your statement under &ldquo;Textiles
and Apparel&rdquo; that your SigNature T DNA and fiberTyping solutions &ldquo;could have significant potential applications&rdquo;
in this market. Similarly much of your disclosure says that your SigNature DNA &ldquo;can provide&rdquo; services in the markets
discussed, which makes it unclear if your products are currently in use in such markets. If you have not made any sales in a particular
market, please move that respective discussion to Future Markets. In addition, please clarify whether your products are used by
the agencies and companies discussed in this section. As currently drafted, it is unclear if you are citing certain agencies or
companies just to provide an overview of each market and the needs in each market, or if these agencies and companies actually
use your products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"><B>Response: </B>The Company acknowledges
the Staff&rsquo;s comments and will make the changes set forth below <B>in bold</B> in its future filings. The disclosure included
under the headings &ldquo;Homeland Security&rdquo; and &ldquo;Law Enforcement&rdquo; in the Present Markets section of the 10-K
will be moved to the Future Markets section, or such disclosure will be updated, as applicable, in the Company&rsquo;s future filings.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Gainsboro 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">50 Health Sciences Drive &bull; Stony Brook, NY 11790 &bull; tel 631 240-8811 &bull; fax 631 240-8900</P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Mr. John Cash<BR>
March 26, 2014<BR>
Page 2</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B></B>Present Markets:</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Microcircuits and other electronics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The global trade in recycled electronics
parts is enormous and growing rapidly, driven by a confluence of cost pressures, increasingly complex supply chains and the huge
growth in the amount of electronic waste sent for disposal around the world. Recycled parts, relabeled and sold as new, threaten
not only military systems but also commercial transportation systems, medical devices and systems, and the computers and networks
that run today&rsquo;s financial markets and communications systems. <FONT STYLE="color: #1C1C1C">The vast majority of counterfeits
discovered in military equipment are semiconductors, the stamp-sized silicon wafers that act as the &ldquo;brains&rdquo; of nearly
every type of modern electronic system. The U.S. military is a huge consumer of these tiny products; a single F-35 Joint Strike
Fighter jet is controlled by more than 2,500 semiconductors</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In 2011, the General Accounting Office
(GAO) issued, under the name of an imaginary OEM, open RFPs on the internet for electronic parts<FONT STYLE="color: #1C1C1C">.
</FONT>All of the part numbers requested were either post-production or entirely fictional<FONT STYLE="color: #1C1C1C">. </FONT>The
GAO received seven prototype parts in response to its RFP:<I> every single one was counterfeit</I><FONT STYLE="color: #1C1C1C">.
</FONT>The explicit costs of counterfeits to the primes start with loss of revenue, licensing fees, and royalties, which in semiconductors
are estimated to be about 2% of TAM (Total Addressable Market) (Jack Stradley, Jack Stradley Consulting, &ldquo;The Cost of Counterfeiting,&rdquo;
p. 6, presentation delivered at Center for Advanced Life Cycle Engineering, Winter, 2012)<FONT STYLE="color: #1C1C1C">. </FONT>In
the over $300 billion semiconductor global market for 2011 this would amount to $15 billion (IHS iSupply, &ldquo;Preliminary Worldwide
Ranking of Top Twenty Suppliers of Semiconductors in 2011&rdquo;)<FONT STYLE="color: #1C1C1C">. </FONT>The proliferation of counterfeit
parts in the supply chain has reached endemic heights<FONT STYLE="color: #1C1C1C">. </FONT>According to the National Electronics
Distributors Association, it has become a $100 billion problem.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In a January 2013 report on a four-year
study conducted between 2005 and 2008, the U.S. Department of Commerce revealed that 39% of 387 companies encountered counterfeit
electronic components, microcircuits, or circuit boards<FONT STYLE="color: #1C1C1C">. </FONT>Some industry statistics even suggest
that counterfeit parts account for 10% of all electronic equipment sold<FONT STYLE="color: #1C1C1C">. </FONT>In fact, counterfeiters
are becoming far more adept at passing off bogus parts by leveraging the same sophisticated technologies that chip manufacturers
use to produce authentic ones<FONT STYLE="color: #1C1C1C">. </FONT>Included in the counterfeiter&rsquo;s toolkit are ovens to bake
recoated parts that use material made from the shavings of the counterfeit parts<FONT STYLE="color: #1C1C1C">. </FONT>In addition,
laser equipment re-marks parts to appear as if they are coming from a specific manufacturer and with a later date code<FONT STYLE="color: #1C1C1C">.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B>The Defense Logistics Agency (&ldquo;DLA&rdquo;),
a component of the U.S. Department of Defense, requires that defense contractors provide items that have been marked with botanically-generated
DNA produced by us or our authorized licensees. DNA marking is required on items falling within Federal Supply Class (FSC) 5962,
Electronic Microcircuits, which have been determined to be at high risk for counterfeiting. A clause at Defense Logistics Acquisition
Directive (DLAD) 52.211-9074, Deoxyribonucleic Acid (DNA) Marking on High Risk Items, is included in new solicitations and contracts
for FSC 5962 items when the item description states that the item requires DNA marking.  As of December 12, 2013, we are providing
unique DNA marks to 27 companies that sell microcircuits and other electronics to the military and other markets.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Gainsboro 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">50 Health Sciences Drive &bull; Stony Brook, NY 11790 &bull; tel 631 240-8811 &bull; fax 631 240-8900</P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Mr. John Cash<BR>
March 26, 2014<BR>
Page 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Our SigNature DNA solution <B>provides
</B>secure, forensic, and cost-effective anti-counterfeiting, anti-piracy and identification solutions to military organizations
and other companies supplying microelectronics and similar products globally in need of securing their supply chains.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Cash-in-Transit</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><I>Cash-in-transit businesses</I> transport
and store cash and ATM cassettes<FONT STYLE="color: #1C1C1C">. </FONT>In the U.K. alone, there is an estimated &pound;500 billion
being transported each year, or &pound;1.5 billion per day<FONT STYLE="color: #1C1C1C">. </FONT>The nature of this business makes
cash-in-transit an attractive target for criminals and as a result the industry invests in excess of &pound;100 million per year
in security equipment and devices<FONT STYLE="color: #1C1C1C">. </FONT>The incidence of cash-in-transit based crime had increased
over 170% in London between 2005 and 2008, according to the Metropolitan Police<FONT STYLE="color: #1C1C1C">. </FONT>Governments
and banks today face the real challenge of staying ahead of increasingly sophisticated counterfeiting without sacrificing security
features and banknote longevity to costs<FONT STYLE="color: #1C1C1C">. </FONT><FONT STYLE="color: #222222">Since 2008, there have
been twenty-two instances where criminals have been convicted of crimes where <B>SigNature DNA</B> forensic evidence has been provided
to UK Police to assist them to secure convictions. These criminal cases have resulted in 71 offenders being convicted and receiving
sentences totaling approximately 350 years of imprisonment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B>We incorporate our SigNature DNA
Markers in cash degradation inks that are used in the cash-in-transit industry.</B> This solvent-based ink marks bank notes if
the cash box is compromised and has the ability to penetrate the bank notes rapidly and permanently. We believe our SigNature DNA
Markers are more resilient and detectable than other competing technologies<I>. </I></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Textiles and Apparel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Cotton classification and the authentication
of cotton geographic origin are issues of global significance, important to brand owners and to governments that must regulate
international cotton trade. We believe that our SigNature T DNA and fiberTyping solutions could have significant potential applications
for the enforcement of cotton trade quotas in the U.S. and across the globe, and for legislated quality improvement within the
industry<FONT STYLE="color: #1C1C1C">. </FONT>We believe that similar issues face the wool and other natural product industries
and have begun to introduce our products to these markets as well<FONT STYLE="color: #1C1C1C">. </FONT>In addition, our digitalDNA
system can be used to provide track and trace capability for labels on finished garments to protect against counterfeiting and
diversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Products containing premium Extra Long
Staple cotton, like Egyptian Giza, Peruvian and American Pima, are recognized by retailers and consumers as being the highest quality
cotton in the industry. These refined high end cottons are well regarded due to their durability and quality which, in turn, typically
commands premium pricing. According to Havocscope and the Coalition Against Counterfeiting and Piracy, the market value of counterfeit
clothing is $12 billion. In recent years, apparel accounted for 14% of the total counterfeit goods seized by U.S. agencies. Cass
Johnson, with the National Council of Textile Organizations says counterfeit fabrics cost a billion dollars every year in lost
tariffs to the US. Britain&rsquo;s fashion industry is worth around $57 million to the economy, but counterfeit clothing and footwear
is estimated to cost designer brands and retailers around $5.4 billion each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B>Our SigNature T DNA anti-counterfeiting
system for DNA marking and authentication of wool and cotton fibers is currently in use by our customers. We are now marking product
in the United States and abroad to assure integrity of the textile supply chain. </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Gainsboro 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">50 Health Sciences Drive &bull; Stony Brook, NY 11790 &bull; tel 631 240-8811 &bull; fax 631 240-8900</P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. John Cash<BR>
March 26, 2014<BR>
Page 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">If you have any questions, please feel
free to contact me at 631-240-8810, or our outside counsel, Merrill M. Kraines, at 212-318-3261.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.5in 3in">Sincerely,<BR>
<BR>
Applied DNA Sciences, Inc.<BR>
<BR>
<BR>
<BR>
<U>/s/ Karol Kain Gray</U><BR>
By: Karol Kain Gray<BR>
Title: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">cc:&#9;Merrill M. Kraines, Fulbright &amp; Jaworski LLP (a member
firm of Norton Rose Fulbright)</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Gainsboro 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">50 Health Sciences Drive &bull; Stony Brook, NY 11790 &bull; tel 631 240-8811 &bull; fax 631 240-8900</P></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!%`4T#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HI*,YZ4`+1110`4444`%%%)D#J:`%HHHH`**3(]:6@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BN(^
M('Q*LO!D:VL$:WFIR#*P;L+&/[S_`-!WKA&^)7Q+LH!JUWH8&GGYB7LG5-O^
M]G(^IH`]RHKFO!'C6Q\:Z2;NV0P7$)"W%NQR8SV(/<'L:P/B!\4T\+WHT;2;
M5;W5"!OW9*1$]!@<LQ]/I0!Z)17A[?$[XB:"T=YKNAC[$Y'$MJT0^@;L?KFO
M6?#'B6P\5Z)%JFGL=C_*\;?>C<=5-`&O17DOBCXO:@^M/HG@[3Q>S(Y0SF,R
M;V'78H[#U-9]G\6_%?A[4XK?QCHQ6"4\MY!BD`]5[-]/UH`[[XHLR_#G6&5B
MI$:X(./XUK"^$MU<P?"V:ZAB:ZN(I)WCB)YD8#(7\36K\1;VWU'X5:E>VDJR
MV\]NCQNO1@77%97P@F>W^%TLZ8WQRSNN>F0,T`6?A?XQ\0^*FU$:W8K$ENR^
M7*D1C&3G*8/7&/\`&O0*\\^%'C?5_&2:F=5%N/LIC\OR8]OWMV<\GT%9WC3X
MMW-EK3:#X5LEO;Q&\N24H7&_NJ*.I'<T`>J45XG#\5O&OAR]B_X2S0S]EE/>
MW,+X_P!D]"?:O5F\3:2OAG_A(S=#^SO)\[S,<X],>N>,>M`&M7C7Q_DDC?0]
MDC+D39VDC^Y5>7XK^-?$=[*/"FAG[-$?X8#,^/\`:/0?2N/\=^,]5\4K8VNM
M:<+.^T\R+)A63=NV]5/(/R_K0!]*Z?\`\@ZV_P"N*?R%6*Q+_7;;P_X=M[NX
M!8F)%CC4\NVWI_\`7KD4\8^+[X&\LM,!M0?X(&=<?7O^%;TZ$ZBYEMYF,ZT8
M.SW'ZR[#XJ6:AV`WP\9XZ5Z-7D=KJ[ZYX\TZ^EA$,C2QJR`Y&1Q7=^+/%4?A
MRWC5(Q-=39\M"<``=S717I2;A!+6QC1J12G-[7.AHKS3_A-O%5CY=W?Z>OV2
M0\;H2@(]F_QKOM,U6VU32X]1@;$+KN.[C9CJ#]*YZE"=-7>QM3K1F[(NT5Y]
MJ'C[4K^_:T\.67G!>DAC+L_N!V'UHL/'NIV%^MIXCLO*5NKB,HR>Y'<?2K^J
M5;7_``ZD_6:=[?CT/0:*Y[QEXLM_"7AF35VC^T,2$@C!P)';ISZ8R?PKS:U\
M8?%O4+-=8L])CELI!O15MU(9?89W$5RG0>U45C/X@AT[PE%KNLD6RBU26=0I
M!5B!\H!YSDX`KRN7XP>+]<NY!X9\/AH$/00/.^/]HJ<"@#OOB5XDUGPQX<2]
MT6T$TKS!'D9"XB7!YP/<`?C6KX0U34-:\+6&HZI:_9;N>/,D>".Y`.#TR,''
MO7)>(?&?B30_AC8:Y/;Q6^K33".>*:$@*"7_`(2<C@"ND\/>)?M'@*U\1ZS+
M'$#;&:=U&%&">@_I0!T=%>)W'Q9\8>(M1EB\(Z*3;Q'J(#,Y'8L>@^GZUK>$
M/BW>S:VF@^+K$6-U(XC28(8\.>@=3TSZT`>K45S'COQK:^"=&6[DB\^YG8I;
MP9QN;'))[`?U%>8GXI_$.WMTUJ?1X_[+=N&-HRQD'T?.?QH`]UHK#\(>*K/Q
M?H,>J6BF,Y*31,<F-QU'OU!!]#7`^*/C+<IK#Z1X3TY;Z5&*&=E9][#KL5>2
M/>@#UJBN%^'WB/Q5JJZC+XKT_P#L^*W1&B=[=H01\VX_,><`"N4U?XOZ]K&L
M/I_@K2C.B$XE,)E>0#^+:.%'UH`]EHKQW1/B]K6EZRFF>-M,^RK(0/.$+1-'
MGN5/!7W'ZUU_Q%\>KX,T>"6UB2YO+TD6X8_(``,L<=1R..^:`.SHKQRU\4?%
MN!H+V\T99+.1E++]F&54GKA3N''K7L=`'S\RV\G[0$BZUM,7]H':)?NGY?W6
M<]ONU[],(FA=9@IB*D.'^[MQSG/:N&^(?PSMO&`%]92)::K&,>8P^68=@V.>
M,<&N+'@/XJ:A"-(OM89-//R,SWFY2OT'S'Z&@!/@U+#'\1=;M[%O]">*0Q`=
M"HE&T_D:9X&DM+OXXZK-J!5IO.N3;;_[X?`Q[A<XK>^&7PZUSPAXKN[R_$!M
M&MWBCD20$L=RD'';(%>?6?AB]\5?$36[/3KM;6[@GGGB=B1DK)TR.1UZT`?0
MOB-;%_#FHKJ>S[']G?S=_3&/Y^GO7C_P<GNK?PQXLE0L(8[?>A]'"/T]\8I9
MOA]\3O$.S3];U?%DK#+2W6]3COM7EC]:]$B\+V/A'X=:CI=CE@+.9I96'S2N
M4.6/^'H*`.(^`"V)CU=SL-^&0<_>$?/3VSU_"NI^,:6#?#V[:\">:KI]F)^]
MYFX=/^`[OPKR+P+X/\0ZW:7.L>&M0%K>V4HCV^88V8$9X;I^!KJX?A=XV\4Z
MA#)XPU8K;1'H9_-?'<*!\HSZ_P`Z`)M,-P?V<;WS]VT%O*S_`'/-']<UM_"?
M_DDUS_OW'\JZ3Q3X9:Z^'MUX<T2"-#Y*101LVT`!@>3]`:I>`O"^I^'_``%/
MH]^D:W;M,5"/N'S#CF@#BO@/Y@L/$1A_UNV+9]</BN*\"_\`"6'7+M_#"Q-J
M(C/FF7R]^W=SC?[]<5ZS\)?!>L^#UU0:O'"GVDQ>7Y<@?.W=G/YBL[QC\)[^
M37&\0>$+P6=V[F1X=YCPYZLC#IGN#_\`6H`PO$&G?%?6-)DLM<CM#9R,,^<]
ML@!!R,-D8-+XFT6_\/\`P/L[&2ZBN,WX>8P2!T0'<0N1P<-C\:F3X9>/?%-W
M"OBS6#':1'/S3B5O^`J.,^YKU0^%-'/A;_A&OLH_L[R?*V9Y]=V?[V><^M`&
M5\+%L5^'FE_8-F#&3-MZ^;GYL^^?TQ7GWQ[CLGUC2%A"G4'C<2A?O%,C9G\=
MV*&^&7CWPM>S+X4U8O:RG.4G$3$=MRGC/N*V/"'PGU!==3Q!XPOA>72.)$AW
MF3+CH78]<>@_^M0!;^(:212Z-%-N$*08;Z\;OTKT:T$"V<(M=OD;!Y>SIMQQ
MBJ'B#0;;Q#IQM9R4=3NBE`Y1O\/:N*3POXVTY#9V-]_HW0%+C:H'T/(_"NU<
ME6E&/-9KN<CYJ=1RM=,2^C@?XK0+:`'$R-)MZ;@,M_\`7IWC91+X[TV)^4*Q
M`@^A<UO^$_!HT.5KZ\F$]ZX(!7[J`]<$]2?6J_B/PUJ>I>+;+4;9(S;PB/>6
MDP>&)/'TK6-6'M$D]$K7,W3G[-NVK=S6\9QJ_A+4`P!Q&&'L017+:&TW_"K=
M3\HG<&DZ>GRY_3-=GXBLI]2T"\L[8*9IH]J!C@9SZUG^#]$NM(T"2QU&./>\
MKDJK;@5(`K"G44:/G>YM.#E5^1G?#-;7^PYVCV_://(E]<8&W\.OZT?$Q;8Z
M%`TFW[0)P(O7&#N_#I^E9][X&UG2K][KPW>%4?HGF;&4>GH152[\$>*-2B-U
M?7237((58Y)<X'?GH/H*Z$J;K>UY]/Q,&YJE[/E-.]\+_P#";_#&RTY[CR9U
M19(96&0&7(&?;&17`'4?B5\,+:-+M%N-*A(1=^)8@.P##YE]LXKT+6O#?B.;
MX?V.FZ/="TU6UD1]RS%.F[(##ZCKQ7%7OA+XK^)X$TC6[R-;'>"[R21X..YV
M#<U>?4:<W;N=L+J*N6_BEKS^(_A9H^KVL;1V]W<JTR9SM(5A@G_>!KN/AHFG
MIX`TK^SMFQH092O4R_QY]\Y_2K$7@K2QX)C\*3JTUFL/EESPQ;.=X]#NYKS(
M?"SQYX<NI4\-:X/LSG(*7#0D_P"\O3-06=1\<_\`D0X_^OV/_P!!:L#Q"9Q^
MSQI?DYV'RA+C^[N/7\=M;WB7PCXGU_X8:?H]PZ7&L1SB2=Y9A@@%_P"+OP17
M1^'O#/E_#ZT\.:W`C_Z,89XU;(ZGH?R.:`/(O!'_``LI?#D9\*K!_9YD;D>1
MN+YYW;N<].O;%+KGA3Q[XDU>S;Q)+I]K*F%6>6>"-E0GKA3EL'..*U)?A?XY
M\+7\S>$=6+VLI_AG$38[;E/RD^X_2M3PI\)]3DUU-?\`&=\+RXC8.L'F&0LP
MZ%V/8>@H`ROCPK#4M`@=RX$+@D]SE037J7B*UA;P+J5L8U\H:=(H7'``C./Y
M5R'Q5\#:WXMU+2Y])CA=+5&$GF2A.201_*N[U>TFO/#U[90@&::U>)`3@;BI
M`Y^M`'DGPB>X'P_\5?9B?.56,8'7=Y1Z>_2IO@#'IY35I#L.HAD`S]X18[>V
M>OX5TWPG\'ZMX1TW4+?5XXE:XE5D$<@?(`P<US_B3X/ZG;ZV^L>#=06T9V+>
M09&C:,GKM8=O8T`=Q\2#./AYK1M\[_LYSCKMR-W_`([FO%_AZ/'HTZZ;P>L!
MA,H$Y/D[]V.,[^<8Z=NM>J^`=$\7VB:E#XQN_ML,Z*D2//YHQ\VX?B"*Y+4_
MA/XF\/:Q)?\`@C4RD4A.(O.\N1!_=)/##ZT`9'B;P_\`$CQ$EM#XD%BBQL3$
M\T]O$1Z\@Y(Z<5V_BSX;3^)/!FC6=O?Q-J&EVZI'*Q/ES#:`1D=.@P:PM(^$
M_B+7=9CU+QQJ1FCB(_<>=YCN!_#GHJ_2NN^(&A>*;Z/39O"%V+26RWJ\:R^7
MN4A<#'W2!CH:`.`'C/XA_#VYMX/$EN;NR+;5,V&W@==LB]\>N:]OM+J.]LX+
MN$DQSQK(A/H1D?SKQJ7P'\1?&=Y:P^++U(;&W;).Z,D>NU4ZG'<U[-;6\=I:
MQ6T*[8H4$:#T`&!0!+1110`5XA\-%8?&3725(!^U<D?]-17M]-$:*Q944$]P
M.:`'5F>)?^16U;_KRF_]`-:=(0",$9!H`\F^`*LNCZON!'^D1]1_LFO6J:J(
MGW$5<^@Q3J`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
<H`****`"BBB@`HHHH`****`"BBB@`HHHH`__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!&`'@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBN2\8?
M$C0O""M#/*;J^QE;2$@L/]X]%'Z^U`'6URWB'XC^%_#>Z.[U%9KA?^7>V_>/
MGWQP/Q(KPWQ1\4?$GB8O$;HV-FW'V>V)4$?[3=6_E[5SFCZ:NKZBEH]_:6(?
MK-=N50?C@T`>D:[\>-4N2T>AZ?%9)VEG_>2?ET'ZUP=[X@\3>)KI4N-0OKZ4
MG*1(S$`^RKP/P%>O^&?@IX;BACN]0OVU@GD>4^V$_P#?)R?SKT73=&TS1H1#
MIMA;VB8QB&,+GZGO0!0\$Q:K!X.TV+6RYOUAQ+YARPY.T-[XQFMVBB@`HHHH
M`****`"BBB@`HHHH`\I^*'Q3;1WET'09<7X^6XN1_P`L>.B_[7/7M]>GC^BZ
M-<^(]3*/=QP*QW375RQVKZDGJ3[54U?[3_;-]]MS]J^T2>=GKOW'/ZU['X93
MX<_\([8YDF\WR5\['F?ZS'S9Q[YK6E!3E9W^1G4DXQNK?,HM\-OA^=,2$>*)
M%O%'S7&058_[F.GX_C7%:WX"FTW=)I^K6.J1#IY+E9/^^3_0FO5]GPY_OS_^
M1:-GPY_OS_\`D6NKZO3[2^XYO;3[Q^\\/T_6=;\.W&ZPO;JQD!Y",5!^HZ'\
M:[W1/CKKMEMCU>T@U&,=77]U)^G!_*NPFMOAI<)LF$DB^C"0_P!*P-7\&_#:
M^C)T_4KO3I>Q5'D3\0PS^1%83P\E\*?W&T:T?M-?>=IHGQ>\):O&/-O6T^;'
M,=TNW\F&0:WAXQ\.D`C5[<@]P37S7K/A2?393]CNH]2@[20HRG\589_G5'3M
M8N]+G4J?,C4_-!)G:?;U'X5*@HNU5-%.3DKTVF?47_"8^'?^@M;_`)FC_A,?
M#O\`T%K?\S7E_ASQ+\/-7@5=1M)]-O.AC,KNC'_98?R/ZUT&SX<_WY__`"+6
M\:5&2O%2?R,95*L='RG8?\)CX=_Z"UO^9K2LK^TU*W%Q97"3Q$XW(<C/I7GN
MSX<_WY__`"+6SI7BCP=HMI]EL;AHXRQ8_NW))/<DBE.@K>Y&5_-#A6=_>:MZ
MG8T51TK6;#6K=I["<2HK;6X((/N#5ZN1IIV9TIIJZ"BBBD,\Q^)/PI3Q`\NL
MZ&%CU-CNFA)PMQQV]&X^AKQ**74O#6JM'+`T%Q"V)+>X0X/LRGJ*^NZP_$O@
M[0_%=MY6JV:NZC"3I\LB?1OZ'BFFT[H32>C/*=$^(?@>YMU35_#0M;KHS0DM
M&WN,G(^A_.NA77O`;H'30'93T88(/_CU<AXF^".MZ87GT65=4MQSY?"3*/IT
M;\/RKAK:]UGPQJ!$9FLKA#AHY8_YJPP?RKHIU[?'=_-F$Z-_ALOD>T_V[X$_
MZ%^3]/\`XJC^W?`G_0OR?I_\57':1\99K=!'JWAW3;W'_+2*,1-^(P0?TKHK
M7XN:!=X`\/VD;'^&0J/UVXKHA5C-V2?_`($8RIRCJ[?^`E_^W?`O_0OR?I_\
M569K(^'FLVS1-HES:RG[MQ;X#J?Q;!_&MA?&\#H'3PE`RGHRJ"#^.RE_X36'
M_H4(O^^/_L*U=-R5G%_^!&:J):J2^X\0UG1GTN=C$YFM2V(Y2,'\1DX-=G\/
M_%FB)"^F>(M)%Y(O,%POWR.ZMR,^QJ[\0/'UE?:'/HD.A6UM<S%=[KC=$`0?
M[HP3BN/\!>9!XIMM0%D;N*TR[Q[<@Y!`!X/K^E<=G&KRQ37E?]3JNI4^:7WV
M/6?[=\"?]"_)^G_Q5']N^!?^A?D_3_XJIO\`A-8?^A0B_P"^/_L*/^$UA_Z%
M"+_OC_["N[DE_*__``(Y.:/=?^`EO3_'OAK2H#!8Z7/;QD[BJ*O)_.M[0?&>
MG>(+UK2VBGCE5"_[Q1@@>X/O7+?\)K#_`-"A%_WQ_P#85+!X_:V)-OX7$1/4
MQY7/Y+6,\/S)V@[^J-(5K-7EIZ'HM%<+:?$2[N+N&`Z!/B1PORL21D^FVBN.
M5"I#='5&M"6S.ZHHHK$U"J&J:)I>MP>1JFGV]VG82Q@D?0]1^%7ZK7^H6>EV
M<EY?W,=M;Q#+R2-@"@#SG6_@7H%[NDTFZGTZ0Y(0_O8_R//ZUYWKGP?\6:/N
M>&U34H1_':-N;'^Z<'\LUZ3K?QQ\.:?NCTR&XU.4<`J/+C_-N?TKSC7_`(P^
M*M:W1V]PFF0'^"U&&Q[N>?RQ0!SVF>)?$GA6Y,5E?W=B\9PT#YV@^A1N/TKI
M;_XT>++W2?L2R6]M*>'NH(RLA'MS@?45S^B^$?$OBZX,ME8W%QO;+W4Q(3/J
M7;K^IKUCPM\#M.L"ESXAN/M\PY^SQY6('W/5OTH`\N\*>"-=\;7Q-LC+`6S/
M>S9V+Z\_Q-["OHSPKX5TWPCHZ:=IR$_Q2S-]^5O4_P!!VK5M[:"TMTM[:%(8
M8QA(XU"JH]@*EH`****`"BBB@`HHHH`****`"N+^*OAVX\1^#9(;:X6%[607
M!#DA7`!!!Q]<_A110!YEX6^"]]KMI%?7>JV]O;2<@1*SN1^.`/UKTW0?A1X3
MT(K)]A^W3K_RUO#OY]E^[^E%%`'9(BQH$10JJ,!5&`*=110`4444`%%%%`!1
)110`4444`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
